Natera president sells $54,881 in stock

Solomon Moshkevich, President, Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), sold 292 shares of common stock on October 21, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at $187.95, for a total transaction value of $54,881. The transaction comes as Natera trades near its 52-week high of $187.34, with the stock showing remarkable strength, delivering a 53% return over the past year. According to InvestingPro analysis, the company currently appears overvalued relative to its Fair Value.

Following the transaction, Moshkevich directly owns 117,267 shares of Natera, Inc.

The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person’s Stock Unit Agreement granted on January 28, 2022.

The sale was executed pursuant to a pre-arranged trading plan under Rule 10b5-1.

In other recent news, Natera has been active with several significant developments. Canaccord Genuity has maintained its Buy rating and a price target of $200 for Natera, emphasizing the company’s leadership in molecular residual disease testing. The company is set to present 14 abstracts at the European Society for Medical Oncology Congress, showcasing advancements in early cancer detection. Additionally, Natera has enrolled over 1,600 patients in its EXPAND trial, which evaluates its Fetal Focus test for noninvasive prenatal testing. This trial aims to confirm test results through prenatal or postnatal diagnostic testing.

In another development, Natera’s Signatera test has shown strong performance in monitoring recurrence and treatment response in early-stage uterine cancer patients. The test also outperformed standard tumor markers in a study on testicular cancer, highlighting its effectiveness in predicting patient outcomes. Wells Fargo has resumed coverage of Natera with an Equal Weight rating and a price target of $175, acknowledging the company’s strong position in cell-free DNA testing technology. These recent activities underline Natera’s ongoing efforts to enhance its testing capabilities across various medical fields.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.